Corbus Pharma: A High-Stakes Pitch for its Cancer and Obesity Drugs

NORWOOD, MA – February 12, 2026 – Clinical-stage biotechnology firm Corbus Pharmaceuticals (NASDAQ: CRBP) is set to take the virtual stage later this month, with CEO Yuval Cohen, Ph.D., scheduled to present a corporate overview at the 36th Annual Oppenheimer Healthcare Life Sciences Conference. For a company navigating the high-risk, high-reward world of drug development, such events are more than just a calendar entry; they are pivotal opportunities to shape the narrative around its science and secure the investor confidence needed to fuel its ambitious pipeline.

Corbus is advancing a diversified portfolio targeting two of medicine's most challenging and lucrative fields: oncology and obesity. The February 25th presentation will provide a platform to update the investment community on its three key programs, each at a critical juncture in its development. With a recently bolstered cash position and a string of encouraging clinical updates, all eyes will be on how the company articulates its path forward and the potential of its novel therapeutic candidates.

A Dual-Pronged Attack on Disease

Corbus’s strategy hinges on a trio of assets, two aimed at cancer and one at obesity. The company's lead oncology candidate, CRB-701, is a next-generation antibody-drug conjugate (ADC) that has already generated significant buzz following impressive data presented at the 2025 European Society for Medical Oncology (ESMO) Congress.

ADCs are often described as “smart bombs” for cancer, designed to deliver a potent cytotoxic payload directly to tumor cells while sparing healthy tissue. CRB-701 targets Nectin-4, a protein highly expressed on the surface of several solid tumors. The data from its Phase 1/2 trial was striking, showing an Objective Response Rate (ORR) of 55.6% in metastatic urothelial cancer, 47.6% in head and neck squamous cell carcinoma (HNSCC), and 37.5% in cervical cancer. Perhaps just as importantly, CRB-701 demonstrated a favorable safety profile, with a low discontinuation rate and a notable absence of the severe skin toxicities and nerve damage that have plagued other Nectin-4 targeting drugs.

Bolstering its oncology franchise is CRB-601, an anti-integrin monoclonal antibody currently in Phase 1 trials. This drug works through a different but complementary mechanism: blocking the activation of TGF-beta, a protein that helps tumors create an immunosuppressive microenvironment. By inhibiting TGF-beta, CRB-601 aims to “uncloak” tumors, allowing the body's own immune system—potentially boosted by checkpoint inhibitors like anti-PD-1 therapies—to attack the cancer. This positions CRB-601 as a potential combination therapy to overcome resistance to existing immunotherapies, a major challenge in cancer treatment.

Rounding out the pipeline is CRB-913, an oral drug for obesity that seeks to succeed where others have failed. It is a CB1 inverse agonist, a mechanism known to promote weight loss but abandoned in its first generation due to severe neuropsychiatric side effects. Corbus’s innovation with CRB-913 is its design as a highly peripherally restricted molecule, meaning it acts primarily in the body and has minimal penetration into the brain. The goal is to deliver the metabolic benefits without the central nervous system risks. Early Phase 1a data released in December 2025 showed a placebo-adjusted mean weight loss of 2.9% in just 14 days in an obese cohort, with no concerning neuropsychiatric signals.

The Investor View: Cash Runway and Market Potential

For any clinical-stage biotech, a promising pipeline is only half the battle; the other half is the capital required to fund it through lengthy and expensive clinical trials. On this front, Corbus appears to be on solid ground. Following a public offering in late 2025 that raised approximately $75 million, the company has stated its cash runway extends into 2028. This financial stability is crucial, as it allows management to execute its clinical strategy from a position of strength rather than desperation.

Wall Street analysts have taken note. The consensus rating for CRBP stock is a “Strong Buy,” with average price targets suggesting a significant upside from its current valuation. This optimism is rooted in the large market opportunities its drugs are targeting and the encouraging data seen thus far. The global obesity drug market is exploding, and while dominated by injectable incretin analogs, there is a clear demand for effective oral therapies and maintenance treatments. Preclinical data suggests CRB-913 could fill this role, potentially being used in combination with or as a follow-on to current blockbusters.

In oncology, the market for ADCs is also expanding rapidly. By demonstrating strong efficacy across multiple tumor types and a superior safety profile, CRB-701 is positioned to compete in a validated but still-evolving space. The two Fast Track designations granted by the FDA for HNSCC and cervical cancer could expedite its path to market, a key catalyst investors will be watching closely.

What to Watch For in 2026

The Oppenheimer conference presentation will be a key forum for Corbus to synthesize these developments for a financially-focused audience. Investors will be listening for updates on timelines and strategy. Key milestones on the horizon include a planned meeting with the FDA in 2026 to discuss the registrational trial design for CRB-701, with the goal of initiating that pivotal study by mid-year.

For the obesity program, the next major data readout will be from the 12-week Phase 1b CANYON-1 study of CRB-913, which is expected in the summer of 2026. This will provide a much clearer picture of the drug's weight-loss efficacy and safety over a longer duration. Meanwhile, progress in the Phase 1 dose-escalation study for the cancer immunotherapy CRB-601 will continue to build the foundation for that program’s future.

The biotech conference circuit is the lifeblood of innovation, connecting scientific vision with the capital needed to make it a reality. As Dr. Cohen prepares for his presentation, he will be speaking not just to analysts and fund managers, but to a broader community hopeful for new solutions to some of the most pressing health challenges. The company's performance at this virtual podium could set the tone for a transformative year.